VivoSeq
0

Pipeline Programs

0

Active Trials

0

Companies Involved

HCV is an early-stage landscape with 0 programs across 0 companies.

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

78/100

Attrition Rate

14/100

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

14

clinical trials

Completed7 · 50%
Unknown status5 · 36%
Terminated1 · 7%
Withdrawn1 · 7%

Trial Activity

14 trials

Telaprevir in Genotype 3 HCV
Completed·QQueen Mary University of London·Phase 4·NCT02087111·14 enrolled
Ombitasvir /Paritaprevir/Ritonavir Plus Ribavirin on HCV GT4
Completed··Phase 1/2·NCT04378608·100 enrolled
Influence of Nevirapine on HCV Viral Load
Unknown status·VValme University Hospital·N/A·NCT01277627·60 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)